Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells

SIMPLE SUMMARY: Although tyrosine kinase inhibitors (TKIs) are highly effective in the treatment of patients with chronic myelogenous leukemia (CML), leukemic stem cells (LSCs) are known to be resistant to TKIs. As a result, the application of immunotherapies against LSCs may cure CML. ABSTRACT: Int...

Descripción completa

Detalles Bibliográficos
Autor principal: Matsushita, Maiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582551/
https://www.ncbi.nlm.nih.gov/pubmed/34771599
http://dx.doi.org/10.3390/cancers13215435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582551/
https://www.ncbi.nlm.nih.gov/pubmed/34771599
http://dx.doi.org/10.3390/cancers13215435

Ejemplares similares